Search
Displaying 1001–1010 of 1059 results for “fc 26 ps4 coins Visit Buyfc26coins.com for latest FC 26 coins news..NH7v”
-
Covid Revealed What Science Can Do When Funding is Found
In the Press‘In some ways, the pandemic ought to make us all feel more upbeat about the long-term future of medical research.’
-
RD Fund Appoints Tony Adamis, MD to Board of Directors
Foundation NewsThe RD Fund announces the appointment of Anthony (Tony) Adamis, MD, to its board of directors.
-
Pediatric Ophthalmologists Target Inherited Retinal Diseases
In the PressNew opportunities continue to develop in an evolving landscape.
-
BioBonds in New York Times: Ask Congress to Support Biomedical Research for Treatments and Cures
In the PressKaren Petrou invented a new funding model for curing blindness. Proposed legislation aims to apply it to medical research more generally.
-
This pages contains a variety of webinars that have been shared on a national level.
-
Foundation News
The free webinar for eye care professionals, on June 21, will feature some of the intriguing and innovative research efforts underway for inherited retinal diseases and AMD.
An overview of the Foundation’s no-cost genetic testing program will also be presented.
-
In the Press
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness. Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness.
-
Foundation Fighting Blindness Appoints Claire M. Gelfman, Ph.D. as Chief Scientific Officer
Foundation NewsDr. Gelfman brings over twenty years of successful ophthalmic research and development experience to the Foundation executive team.
-
Investing in Cures Summit 2021
The 2021 Investing in Cures Summit (ICS) convenes key stakeholders of the Foundation Fighting Blindness and RD Fund to learn from the world’s leading industry, clinical and retinal science innovators poised to take emerging therapies across the finish line.
-
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
In the PressFormer Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
